AmSurg (NAS: AMSG) reported earnings on April 24. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), AmSurg beat expectations on revenues and earnings per share.
Compared with the prior-year quarter, revenue grew significantly and GAAP earnings per share increased significantly.
Margins dropped across the board.
AmSurg logged revenue of $230.2 million. The 10 analysts polled by S&P Capital IQ expected to see a top line of $219.7 million on the same basis. GAAP reported sales were 28% higher than the prior-year quarter's $179.4 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.50. The 11 earnings estimates compiled by S&P Capital IQ averaged $0.48 per share. GAAP EPS of $0.47 for Q1 were 24% higher than the prior-year quarter's $0.38 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 54.5%, 160 basis points worse than the prior-year quarter. Operating margin was 30.7%, 90 basis points worse than the prior-year quarter. Net margin was 6.4%, 10 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $228.4 million. On the bottom line, the average EPS estimate is $0.50.
Next year's average estimate for revenue is $922.9 million. The average EPS estimate is $2.01.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 144 members out of 151 rating the stock outperform, and eight members rating it underperform. Among 59 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 56 give AmSurg a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on AmSurg is hold, with an average price target of $28.00.
Over the decades, small-cap stocks like AmSurg have provided market-beating returns, provided they're value-priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Get instant access to this free report.
Add AmSurg to My Watchlist.
At the time thisarticle was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings. He is the co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.